IP Library Granted Patent US 10,441,641
Granted Patent B2
US 10,441,641 · App. 14/852,990 · Granted Oct 15, 2019

Botulinum toxin and the treatment of primary disorders of mood and affect

Inventor: Gary E. Borodic (Canton, MA)
Assignee: REVANCE THERAPEUTICS, INC.
A61K38/4893A61K9/0019A61K9/0021A61K9/08A61K9/1075A61K47/10A61K47/44A61K49/0004C12Y304/24069A61K2121/00Y02A50/469
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,441,641
App. No.
14/852,990
Granted
Oct 15, 2019
Kind
B2
Abstract

A method of treating circadian rhythm disorders includes identifying a subject with a circadian rhythm disorder or at least one symptom of a circadian rhythm disorder and administering an effective amount of a composition comprising a botulinum toxin and a pharmaceutically acceptable carrier to said subject thereby reducing at least one symptom of a circadian rhythm disorder.

Claims (12)

1. A method for simultaneously treating both sleep disorder and depression comprising:

(i) identifying a subject with both sleep disorder and depression; and

(ii) administering an effective amount of a composition comprising a botulinum toxin immunotype A and a pharmaceutically acceptable carrier to the subject, thereby reducing at least one symptom of both sleep disorder and depression;

wherein said sleep disorder is sleep onset insomnia or sleep maintenance insomnia.

2. The method of claim 1 , wherein the botulinum toxin is botulinum toxin type A from Hall strain Clostridium botulinum.

3. The method of claim 1 , wherein the composition is administered by an injection.

4. The method of claim 3 , wherein the step of administering the composition to the subject further comprises at least two injections sites, wherein the injections are multifocal.

5. The method of claim 3 , wherein the composition is administered to at least one of a forehead, scalp, neck, or periocular region of the subject.

6. The method of claim 3 , wherein the injection is transcutaneous, subcutaneous, transdermal, or intramuscular.

7. The method of claim 1 , wherein the effective amount of the composition is a dose between 5-3000 units.

8. The method of claim 1 , wherein the composition decreases choline acetyltransferase activity.

9. The method of claim 1 , wherein the composition decreases synthesis of acetylcholine.

Assignments (8)
SECURITY INTEREST Recorded Feb 17, 2025
From: REVANCE THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 070239/0739 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0663 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2025
From: ATHYRIUM BUFFALO LP
To: REVANCE THERAPEUTICS, INC
Reel/Frame 070153/0630 →
SECURITY INTEREST Recorded Mar 18, 2022
From: REVANCE THERAPEUTICS, INC.
To: ATHYRIUM BUFFALO LP
Reel/Frame 059437/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2016
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 038870/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2016
From: BORODIC, GARY E, DR
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 038249/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2016
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: BORODIC, GARY E.
Reel/Frame 038096/0402 →